The results imply that JZG had a better therapeutic effect on DSS-induced NASH in rats through effective reduction of the levels of serum ALT, AST, serum endotoxin, LDL-C, TC and TG in NASH rats, as well as increased serum HDL-C and SOD levels. Here, SOD1 is linked to metabolic dysfunction-associated steatohepatitis.